We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bio-Innovation Agreement to Strengthen Ties between Canada and Israel

By LabMedica International staff writers
Posted on 31 May 2016
Print article
A recently signed agreement aims at encouraging academic and entrepreneurial ties in the field of bio-innovation between a Canadian and an Israeli university.

The agreement will establish a strong relationship between the University of Toronto (Canada) – in the form of the Institute of Biomaterials and Biomedical Engineering – and The Hebrew University of Jerusalem (Israel) – in the form of the Alexander Grass Center for Bioengineering.

The agreement, which is called the Jerusalem-Toronto Bio-Innovation Partnership, will strengthen the exchange of students, faculty, and ideas between the academic and entrepreneurial environments of the two universities. In addition, it will provide financial support for students in engineering, biology, and computer science to conduct research in the partner country over a 12-week period.

An intensive eight-week educational program – the Transdisciplinary Innovation Program – that weaves together computer vision, big data, and bioengineering will also be offered to students from the University of Toronto, enabling interaction with Nobel laureates, work under the mentorship of Israeli scientists and entrepreneurs, and the opportunity for students to pitch ideas to investors.

Faculty and student groups will travel between the two countries to advance the collaboration, and a joint BioDesign program will bring together engineers, clinicians, and business and engineering students to share and create knowledge with tangible impact.

Dr. Meric Gertler, president of the University of Toronto, said, “The forthcoming projects with The Hebrew University of Jerusalem are important to the University of Toronto. They underscore a commitment on the part of both universities to harness the power of Israel’s and Canada’s brightest minds to find solutions to the world's pressing social and medical problems. They will provide exciting opportunities in the near-term and, I believe, stand to have meaningful long-run impact by virtue of the skills investment and advances they entail.”

Dr. Menahem Ben-Sasson, president of The Hebrew University of Jerusalem, said, “The Hebrew University is very pleased to expand its partnership with the University of Toronto. This agreement will bring about new exchanges of people and ideas between two of the world’s leading centers of research and academia. Furthermore it will drive cooperation in medical, social and entrepreneurial studies and research that will benefit Canada, Israel and the entire world.”

Related Links:
University of Toronto
The Hebrew University of Jerusalem

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.